Orencia Patent Appeal Not Moot, Momenta Tells Fed. Circ.
An infringement case over a Bristol-Myers Squibb Co. patent covering its Orencia biologics product is not moot simply because challenger Momenta Pharmaceuticals Inc. is considering stopping development of a proposed biosimilar,...To view the full article, register now.
Already a subscriber? Click here to view full article